Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD)

NCT ID: NCT05443464

Last Updated: 2022-12-23

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-06-05
• Study Completion Date: 2024-10-14

Brief Summary

The objective of this clinical study is to demonstrate safety and feasibility of single-dose infusion of Ossium MSCs product (OSSM-001) to treat steroid refractory acute GVHD (SR-aGVHD).

Detailed Description

The dose escalation will be used to establish a maximum tolerated dose, starting from 2M cells/kg. If no safety issues are seen, then MSCs dose maybe escalated to 6M cells/kg, 12M cells/kg and 24M cell/kg based on data review from each cohort. Additional studies will be conducted to establish a dosing regimen and to evaluate the safety and efficacy of OSSM-001 for SR-aGVHD patients.

Conditions

GVHD,Acute

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

2M cells/kg

Dose level 1. 3 subjects will receive OSSM-001 at 2M cells/kg and followed for 28 days post dose to observe for DLT.

Group Type: EXPERIMENTAL

OSSM-001

Intervention Type: BIOLOGICAL

Direct IV infusion of OSSM-001

6M cells/kg

Dose level 2. If no DLTs are observed in the previous dose level, 3 subjects will receive OSSM-001 at 6M cells/kg and followed for 28 days post dose to observe for DLT.

Group Type: EXPERIMENTAL

OSSM-001

Intervention Type: BIOLOGICAL

Direct IV infusion of OSSM-001

12M cells/kg

Dose level 3. If no DLTs are observed in the previous dose level, 3 subjects will receive OSSM-001 at 12M cells/kg and followed for 28 days post dose to observe for DLT.

Group Type: EXPERIMENTAL

OSSM-001

Intervention Type: BIOLOGICAL

Direct IV infusion of OSSM-001

24M cells/kg

Dose level 4. If no DLTs are observed in the previous dose level, 3 subjects will receive OSSM-001 at 24M cells/kg and followed for 28 days post dose to observe for DLT.

Group Type: EXPERIMENTAL

OSSM-001

Intervention Type: BIOLOGICAL

Direct IV infusion of OSSM-001

Interventions

OSSM-001

Direct IV infusion of OSSM-001

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Minimum 18 years of age who have undergone hematopoietic cell transplantation (HCT), from any donor source donor (including HLA-matched related and unrelated, haploidentical and umbilical cord donors) with any conditioning regimen

2. Clinically diagnosed Grades II to IV acute GVHD as per standard criteria occurring within 100 days of HCT

3. Confirmed diagnosis of steroid refractory aGVHD defined as patients administered high-dose systemic corticosteroids (methylprednisolone 2 mg/kg/day [or equivalent prednisone dose 2.5 mg/kg/day]), given alone or combined with calcineurin inhibitors (CNI) and either:

1. Progressing based on organ assessment after at least 3 days at the time of initiation of high-dose systemic corticosteroid +/- CNI for the treatment of Grade II-IV aGVHD, OR

2. Failure to achieve at a minimum partial response based on organ assessment after 7 days compared to organ stage at the time of initiation of high-dose systemic corticosteroid +/- CNI for the treatment of Grade II-IV aGVHD, OR

3. Patients who fail corticosteroid taper defined as fulfilling either one of the following criteria:

i. Requirement for an increase in the corticosteroid dose to methylprednisolone ≥2 mg/kg/day (or equivalent prednisone dose ≥2.5 mg/kg/day), OR

ii. Failure to taper the methylprednisolone dose to <0.5 mg/kg/day (or equivalent prednisone dose <0.6 mg/kg/day) for a minimum 7 days.

4. Minimum Karnofsky Performance Level of at least 30 or higher at the time of study entry.

Exclusion Criteria

1. Has received more than one systemic treatment for steroid refractory aGVHD in addition to steroids.

2. Received stem cell therapy in the past

3. Presence of an active uncontrolled infection including significant bacterial, fungal, viral, or parasitic infection requiring treatment

4. Presence of relapsed primary malignancy, or who have been treated for relapse after the HCT was performed, or who may require rapid immune suppression withdrawal as pre-emergent treatment of early malignancy relapse.

5. Evidence of pulmonary infiltrate or hemorrhage based on imaging or requiring high flow oxygen via face mask

6. Patients who have had treatment with any other investigational agent, device, or procedure within 30days (or 5 half-lives, whichever is greater) prior to enrollment.

7. Patients who have received more than one HCT

8. Any medical or psychological condition or situation deemed by the Investigators to put the patient at increased risk of complications or non-compliance.

9. Unresolved veno-occlusive disease

10. HLA antibody screen positive for HLA antibodies specific against the MSCs products

11. ALT or AST > 5X of upper limit of normal

12. Serum Bilirubin >2 X of upper limit of normal

13. GFR <50 ml/min

14. SpO2 <94% despite being on continuous supplemental oxygen

15. Patients requiring continuous >4L/minute of supplemental oxygen (irrespective of oxygen saturation)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ossium Health, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sagar Munjal

Role: STUDY_DIRECTOR

Ossium Health, Inc.

Other Identifiers

OSSM-001-006-01

Identifier Type: -

Identifier Source: org_study_id